

C₂ CryoBalloon[®]

Ablation System

CHANGE HOW YOU TREAT BARRETT'S ESOPHAGUS

Target abnormal mucosa,
preserve healthy tissue,
proactively prevent disease.¹



C2 CryoBalloon System Addresses Unmet Needs

Patients with Barrett's Esophagus (BE) are at an increased risk of developing esophageal cancer.²


Eradication of abnormal mucosa is the primary goal of treatment. Although traditional approaches destroy lesions, it can also result in cellular death of healthy tissue, while cryoablation preserves the underlying tissue architecture and extracellular matrix.³

Improve Patient Comfort

Unlike other therapies, cryoablation offers precise and controlled endoscopic treatment. Patients treated with the C2 CryoBalloon report significantly less post-procedural pain and need for narcotic medication compared with radiofrequency ablation.⁴⁻⁶

Exceed Expectations^{4,7}

The C2 CryoBalloon is indicated to treat both BE and gastric antral vascular ectasia (GAVE), making it a vital part of your comprehensive offering.



C2 CryoBalloon System

A targeted approach
to cryoablation



Experience A New Level of Efficiency

Smart, intuitive interface on the hand-held touchscreen controller for simple set-up while providing feedback to the user.



Precise and Targeted Ablation

Foot pedal enables physicians to precisely target and ablate diseased tissue with nitrous oxide delivered via balloon catheter, while sparing healthy tissue.¹



Destroy Diseased Mucosa

Focal and 180° balloons, in standard and pear shapes, are transparent and compliant, offering direct visualization and controlled spray to eradicate diseased tissue in short and long segments of BE as well as GAVE.

C₂ CryoBalloon[®]

Ablation System

View the
Quick
Reference
Guide



PRODUCT FACTS

	C2 CRYOBALLOON 180° Catheter	C2 CRYOBALLOON FOCAL Catheter
Compliant balloon material	✓	✓
Multiple balloon shapes	✓	✓
Maximum treatment length	3.0 cm	1.5 cm
Minimum treatment length	0.5 cm	1.5 cm
Designed to specifically treat gastroesophageal junction (GEJ)	✓	✓
Compatible with therapeutic scope	✓	✓
Median Procedure time (median Ablation time)	14 minutes (5 minutes) ²	18 minutes (9 minutes) ⁴



C2 CryoBalloon Controller



C2 CryoBalloon Foot Pedal



C2 CryoBalloons: Focal and 180° Standard and Pear shapes



C2 CryoBalloon SideCar



C2 CryoBalloon Cartridge (5 Pack)



C2 CryoBalloon EndoGrip (5 Pack)



C2 CryoBalloon NitroClip



C2 CryoBalloon Storage Case

ORDERING INFORMATION

Catalog Number	Description
Controller and Foot Pedal	
FG-1017	C2 CryoBalloon Controller
FG-1018	C2 CryoBalloon Foot Pedal
Catheters	
FG-1028	C2 CryoBalloon Focal Standard Catheter
FG-1024	C2 CryoBalloon Focal Pear Catheter
FG-1056	C2 CryoBalloon 180° Standard Catheter
FG-1055	C2 CryoBalloon 180° Pear Catheter
Accessories	
FG-1011	C2 CryoBalloon SideCar™
FG-1013	C2 CryoBalloon Cartridge (5 Pack)
FG-1040	C2 CryoBalloon EndoGrip™ (5 Pack)
FG-1050	C2 CryoBalloon NitroClip™
FG-1054	C2 CryoBalloon Storage Case

1. Dbouk et al. 2022. "Durability of CryoBalloon Ablation in Neoplastic Barrett's Esophagus." *Tech Innov Gastroint Endosc* 24, no. 2: 136–44. doi: 10.1016/j.tige.2021.11.007.
2. Fitzgerald. 2026. "Barrett's Esophagus." *N Engl J Med* 394, no. 17 (Apr): 1723–35. doi: 10.1056/NEJMcp2506887.
3. Xiao, Ted & Patel, Shree & Sunkara, Nishita & Joshi, Virendra. (2025). Freeze the Disease: Advances the Therapy for Barrett's Esophagus and Esophageal Adenocarcinoma. *Cancers*. 18. 59. 10.3390/cancers18010059.
4. Canto et al. 2018. "Multifocal Nitrous Oxide CryoBalloon Ablation with or without EMR for Treatment of Neoplastic Barrett's Esophagus (with video)." *Gastrointest Endosc* 88, no. 3 (Sep): 438–46.e2. doi: 10.1016/j.gie.2018.03.024.
5. Schölvinck et al. 2015. "Treatment of Barrett's Esophagus with a Novel Focal Cryoablation Device: A Safety and Feasibility Study." *Endoscopy* 47, no. 12: 1106–12. doi: 10.1055/s-0034-1392417.
6. van Munster et al. 2018. "Focal CryoBalloon versus Radiofrequency Ablation of Dysplastic Barrett's Esophagus: Impact on Treatment Response and Postprocedural Pain." *Gastroint Endosc* 88, no. 5 (Nov): 795–803. e2. doi: 10.1016/j.gie.2018.06.015.
7. Wani et al. 2017. "Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium." *Gastrointest Endosc* 86, no. 1: 1–17.e3. doi: 10.1016/j.gie.2017.03.010.

Before using, refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.



Understand. Innovate. Deliver.™

merit.com

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
1.801.253.1600
1.800.35.MERIT

Merit Medical Europe, Middle
East & Africa (EMEA)
Amerikalaan 42, 6199 AE
Maastricht-Airport
The Netherlands
+31 43 358 82 22

Merit Medical Ireland Ltd.
Parkmore Business Park West
Galway, Ireland
+353 (0) 91 703 733